HSE have published their latest bulletins:
Upcoming GB active substance expiry dates
Biocidal products must be phased off the GB marketThe active substance/product type combinations listed below are due to expire under the GB Biocidal Products Regulation (GB BPR) on the following dates:
- (±)-5-amino-1-(2,6-dichloro-α,α,α,-trifluoro-p-tolyl)-4-trifluoromethylsulfinylpyrazole-3-carbonitrile (1:1) (Fipronil) (CAS 120068-37-3 EC 424-610-5) in product type 18 (30 September 2023)
- (RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin (Warfarin) (CAS 81-81-2 EC 201-377-6) in product type 14 (30 June 2024)
- Chlorophacinone (CAS 3691-35-8 EC 223-003-0) in product type 14 (30 June 2024)
- Polyhexamethylene biguanide hydrochloride with a mean number-average molecular weight (Mn) of 1600 and a mean polydispersity (PDI) of 1.8 (PHMB (1600;1.8)) (CAS 27083-27-8 / 32289-58-0 EC n/a) in product types 2, 3 and 11 (30 June 2024)
- cis-Tricos-9-ene, (Z)-Tricos-9-ene (Muscalure) (CAS 27519-02-4 EC 248-505-7) in product type 19 (30 September 2024)
Once the approvals expire, the active substances can no longer be used in biocidal products of the relevant product types in Great Britain.
If you hold an affected GB BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision.
If you are aware of any disproportionate negative effects that are likely to arise from the expiry of any of the active substance/product type combinations listed above, please contact us.
Active substance no longer supported in GB
Non-approval decision to be taken for unsupported active substance in GB
Following an opportunity for any person, company or taskforce/consortium to support the active substance/product type combination listed below in the GB Review Programme, no compliant notification was received:
- Chrysanthemum cinerariaefolium, extract from open and mature flowers of Tanacetum cinerariifolium obtained with supercritical carbon dioxide (CAS 89997-63-7 EC 289-699-3) in product type 19
In cases where active substance/product type combinations are not supported, GB biocides regulations require that these active substance/product type combinations are subject to a GB non-approval decision.
Once a decision is taken, biocidal products containing this active substance in the relevant product types will have to be removed from the GB market. HSE will provide separate updates on the decision and relevant phase-out periods.
Important: If you are aware of any disproportionate negative effects that are likely to arise from the non-approval of any of the active substance/product type combinations listed above, please contact us by 26 July 2023.
Classification Labelling and Packaging (CLP)
ECHA public consultation: call for comments (Deadline: 11 August 2023)
The Great Britain Mandatory Classification and Labelling (GB MCL) process includes the consideration of information gathered from public consultations, conducted by HSE or international bodies such as the European Chemicals Agency (ECHA).
ECHA has announced public consultations on the following proposals for harmonised classification and labelling (CLH):
- piperonal; 1,3-benzodioxole-5-carbaldehyde (EC: 204-409-7; CAS: 120-57-0). Chemical registered under REACH. Health hazard classes open for commenting
- trihydrogen pentapotassium di(peroxomonosulfate) di(sulfate) (EC: 274-778-7; CAS: 70693-62-8). Biocide active substance. All hazard classes open for commenting
UK-based businesses with an interest in the proposal are strongly encouraged to share any relevant information.
Scientific and technical information should be submitted directly to ECHA using their commenting webform by 11 August 2023. Comments will be published on ECHA’s website.
If your business is affected by the GB CLP Regulation, please also consider if you are likely to be affected by the classification and labelling proposal and let us know at an early stage if you anticipate any significant impacts or benefits.
Information on wider policy and impact considerations can be submitted to HSE at GBCLP.GBMCL@hse.gov.uk.
Under the GB CLP Regulation, HSE will consider all published opinions of the Committee of Risk Assessment of ECHA (RAC) before publishing its own Agency Technical Reports and Agency Opinions, so any information you provide will be important in any final GB MCL decision.
More information on the new GB MCL system is available on the HSE website.